Madrigal Pharmaceuticals
$499.40Change from previous close: −0.06%Absolute change: −$0.31
At a glance
- Revenue growth
- +432.05%
- 2025 vs 2024
- Net margin
- -30.1%
- 2024: -258.6%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | 23.3 | -167 | -133 | 79.9 | -47.1 | — |
| Depreciation and amortization | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | — |
| Capital expenditure | -4.3 | -3.8 | — | — | — | — |
| Investing cash flow | 34.2 | 192 | 27.6 | -207 | 47.9 | — |
| Financing cash flow | 3.1 | 2.3 | 9.0 | 237 | 1.7 | — |
| Debt issued | — | — | 0.0 | — | — | — |
| Debt repaid | — | — | 0.0 | — | — | — |
| Effect of exchange rates | 0.1 | 1.3 | — | — | 0.0 | 0.0 |
| Net change in cash | 60.6 | 27.1 | -96.9 | 110 | 2.5 | — |
| Free cash flow | 19.1 | -171 | -133 | 76.0 | -47.1 | — |